Unknown label

Benjamin ORY

Associate Professor - Team leader of "EpiStress" team of INSERM 1238

Contact details

Pathophysiology of Bone resorption and Therapy of Primary Bone Tumors Laboratory INSERM U957 Nantes University-School of Medicine 1 rue Gaston Veil 44035 Nantes cedex 1 France

Office
106
Phone
02-72-64-11-42
Fax
02-40-41-28-60
Email
Benjamin.Ory@univ-nantes.fr
Personal Website
http://www.umr1238.univ-nantes.fr/35145735/0/fiche___pagelibre/&RH=1279531575411&RF=1234197817591

Taught academic discipline(s)

Histology, Embryology, Nantes University-School of Medicine

Activities / Resume

2004/2007: Phd student, Biological activities of Zoledronic acid on bone tumors, INSERM ERI-7 Pathophysiology of Bone resorption and Therapy of Primary Bone Tumors (Faculty of Medicine, Nantes - France) directed by Dominique HEYMANN

2008/2011: Postdoctoral fellow, implication of the microRNAs in the p63/p73 network, Harvard Medical School, MGH Cancer center, Leif Ellisen, MD, PhD

2011/present: Associate Professor, Functional analysis of microRNAs in the pathogenesis of bone tumors: Role of the microRNAs in the metastatic dissemination and chemoresistance. INSERM U957, Pathophysiology of Bone resorption and Therapy of Primary Bone Tumors (Faculty of Medicine, Nantes - France)


2015: Habilitation à Diriger les Recherches (HDR), Université de NANTES
2017: Direction de l'équipe EpiStress de l'unité INSERM U1238

Additional informations

Chief Editor: OncomiRs (http://versita.com/oncom/)

Main Publications:

Baud'huin M, Lamoureux F, Jacques C, Rodriguez Calleja L, Quillard T, Charrier C, Amiaud J, Berreur M, Brounais-LeRoyer B, Owen R, Reilly GC, Bradner JE, Heymann D, Ory B.
Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis.
Bone. 2017 Jan

Jacques C, Calleja LR, Baud'huin M, Quillard T, Heymann D, Lamoureux F, Ory B.
miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors.
Oncotarget. 2016 Jul

Jacques C, Lamoureux F, Baud'huin M, Rodriguez Calleja L, Quillard T, Amiaud J, Tirode F, Rédini F, Bradner JE, Heymann D, Ory B.
Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Oncotarget. 2016 Apr

Rodriguez Calleja L, Jacques C, Lamoureux F, Baud'huin M, Tellez Gabriel M, Quillard T, Sahay D, Perrot P, Amiaud J, Charrier C, Brion R, Lecanda F, Verrecchia F, Heymann D, Ellisen LW, #Ory B#.
ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis.
Cancer Res. 2016 Jun

Ory B, Baud'huin M, Verrecchia F, Royer BB, Quillard T, Amiaud J, Battaglia S, Heymann D, Redini F, Lamoureux F.
Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.
Clin Cancer Res. 2016 May

Lamoureux F, Baud'huin M, Rodriguez Calleja L, Jacques C, Berreur M, Rédini F, Lecanda F, Bradner JE, Heymann D, Ory B.
Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle.
Nat Commun. 2014 Mar 19

Ory B
, Ramsey MR, Wilson C, Vadysirisack DD, Rothenberg MS, Rocco JW, Ellisen LW. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest. 2011 Feb 1;121(2):809-20.

Ory B and Ellisen LW. A microRNA-dependent circuit controls p63/p73 homeostasis, cell survival and chemosensitivity: p53 family cross-talk meets therapeutic opportunity. Oncotarget. 2011 Mar;2(3):259-64.

Vadysirisack D, Baenke F, Ory B, Lei K, Ellisen LW. Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol Sept 6, 2011.

Ramsey MR, He L, Forster N, Ory B, Ellisen LW. Physical Association of HDAC1 and HDAC2 with p63 Mediates Transcriptional Repression and Tumor Maintenance in Squamous Cell Carcinoma. Cancer Res. 2011 Jul 1;71(13):4373-9.

Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis M, Shultz LD, Mönkkönen J, Rédini F, Heymann D. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of Ras. Cancer Res. 2010;70(24):10329-39.

Ory B, Moriceau G, Rédini F, Rogers M.J, Heymann D. Zoledronic acid resistance mechanisms of osteosarcoma cell lines. J Cell Mol Med. 2008, 12 (3): 928-941.

Ory B, Moriceau G, Redini F, Heymann D. mTOR inhibitors (rapamycin and their derivatives) and nitrogen-bisphosphonates: bi-functional compounds for the treatment of bone tumors. Curr Med Chem. 2007, 14: 1381-1387.

Ory B, Blanchard F, Battaglia S, Gouin F, Redini F, Heymann D (2007). Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 2007, 71: 333-343.

Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and extends overall survival of osteosarcoma-bearing mice. Cancer. 2005, 104: 2522-2529.

Complete list at:

http://www.ncbi.nlm.nih.gov/pubmed?term=ory%20b